Patents by Inventor Michael Thiele
Michael Thiele has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230365671Abstract: The invention refers to anti-oxMIF antibodies with improved properties such as reduced aggregation potential and reduced hydrophobicity due to selected amino acid substitutions in the light and heavy chain variable domains and optionally increased effector functions due to further substitutions in the heavy chain constant regions, and their use in the treatment of oxMIF-related conditions.Type: ApplicationFiled: October 1, 2021Publication date: November 16, 2023Inventors: Alexander SCHINAGL, Irina MIRKINA, Randolf KERSCHBAUMER, Robert Michael THIELE
-
Patent number: 11402388Abstract: The present invention pertains to the specific detection of MIF, in particular oxMIF, in tissues. A detection method is provided which uses immunohistochemistry and wherein specific anti-oxMIF antibodies are used.Type: GrantFiled: July 9, 2013Date of Patent: August 2, 2022Assignee: Takeda Pharmaceutical Company LimitedInventors: Michael Thiele, Randolf Kerschbaumer, Dirk Voelkel, Patrice Douillard, Friedrich Scheiflinger, Alexander Schinagl
-
Patent number: 10613100Abstract: The present invention pertains to the specific detection of MIF, in particular oxMIF, and of anti-oxMIF antibodies in tissues. A detection method is provided which uses immunohistochemistry or immunofluorescence and wherein specific anti-oxMIF antibodies and specific idiotypic monoclonal rabbit antibodies are used.Type: GrantFiled: January 2, 2015Date of Patent: April 7, 2020Assignees: Baxalta Incorporated, Baxalta GmbHInventors: Alexander Schinagl, Michael Thiele, Patrice Douillard, Gerhard Antoine, Randolf Kerschbaumer
-
Publication number: 20180155419Abstract: The present invention pertains to anti-MIF antibodies, preferably in combination with cancer therapeutics, i.e. chemotherapeutic agents, in the treatment of cancers containing mutant TP53 and/or mutant RAS.Type: ApplicationFiled: May 18, 2016Publication date: June 7, 2018Inventors: Patrice Douillard, Randolf Kerschbaumer, Michael Thiele, Salim Yazji
-
Patent number: 9958456Abstract: The present invention pertains to the recognition that a specific oxMIF form of MIF is useful as a diagnostic marker in (MIF-related) diseases, in particular for example monitoring of disease progression. The present invention also pertains to the respective use of a diagnostic kit and a respective diagnostic assay and pertains to advantageous respective antibodies.Type: GrantFiled: October 4, 2012Date of Patent: May 1, 2018Assignees: Baxalta Incorporated, Baxalta GmbHInventors: Michael Thiele, Randolf J. Kerschbaumer, Dirk Voelkel, Patrice Douillard, Friedrich Scheiflinger
-
Publication number: 20160334414Abstract: The present invention pertains to the specific detection of MIF, in particular oxMIF, and of anti-oxMIF antibodies in tissues. A detection method is provided which uses immunohistochemistry or immunofluorescence and wherein specific anti-oxMIF antibodies and specific idiotypic monoclonal rabbit antibodies are used.Type: ApplicationFiled: January 2, 2015Publication date: November 17, 2016Inventors: Alexander Schinagl, Michael Thiele, Patrice Douillard, Gerhard Antoine, Randolf Kerschbaumer
-
Publication number: 20150309012Abstract: The present invention pertains to a robust, precise and easy-to-use assay for potency of anti-MIF antibodies. In particular, the invention discloses an anti-MIF antibody-cell migration assay and respective method and kit.Type: ApplicationFiled: December 5, 2013Publication date: October 29, 2015Inventors: Michael Thiele, Randolf Kerschbaumer
-
Publication number: 20150160235Abstract: The present invention pertains to the specific detection of MIF, in particular oxMIF, in tissues. A detection method is provided which uses immunohistochemistry and wherein specific anfi-oxMIF antibodies are used.Type: ApplicationFiled: July 9, 2013Publication date: June 11, 2015Inventors: Michael Thiele, Randolf Kerschbaumer, Dirk Voelkel, Patrice Douillard, Friedrich Scheiflinger, Alexander Schinagl
-
Publication number: 20150023978Abstract: The present invention relates to monoclonal antibodies and antigen-binding portions thereof that specifically bind to the C-terminal or the center region of macrophage migration inhibitory factor (MIF). These anti-MIF antibodies and antigen-binding portions thereof further inhibit human MIF biological function. The invention also relates to isolated heavy and light chain immunoglobulins derived from anti-MIF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to a method of identifying anti-MIF antibodies, pharmaceutical compositions comprising these antibodies and a method of using these antibodies and compositions for the treatment of MIF-related conditions.Type: ApplicationFiled: January 17, 2014Publication date: January 22, 2015Applicants: Baxter International Inc., Dyax Corp., Baxter Healthcare SAInventors: Randolf Kerschbaumer, Friedrich Scheiflinger, Manfred Rieger, Michael Thiele, Geert C. Mudde, Juergen Muellberg, Rene Hoet
-
Publication number: 20140248638Abstract: The present invention pertains to the recognition that a specific oxMIF form of MIF is useful as a diagnostic marker in (MIF-related) diseases, in particular for example monitoring of disease progression. The present invention also pertains to the respective use of a diagnostic kit and a respective diagnostic assay and pertains to advantageous respective antibodies.Type: ApplicationFiled: October 4, 2012Publication date: September 4, 2014Inventors: Michael Thiele, Randolf J. Kerschbaumer, Dirk Voelkel, Patrice Douillard, Friedrich Scheiflinger
-
Patent number: 8668909Abstract: The present invention relates to monoclonal antibodies and antigen-binding portions thereof that specifically bind to the C-terminal or the center region of macrophage migration inhibitory factor (MIF). These anti-MIF antibodies and antigen-binding portions thereof further inhibit human MIF biological function. The invention also relates to isolated heavy and light chain immunoglobulins derived from anti-MIF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to a method of identifying anti-MIF antibodies, pharmaceutical compositions comprising these antibodies and a method of using these antibodies and compositions for the treatment of MIF-related conditions.Type: GrantFiled: April 26, 2010Date of Patent: March 11, 2014Assignees: Baxter International Inc., Baxter Healthcare S.A., Dyax Corp.Inventors: Randolf Kerschbaumer, Friedrich Scheiflinger, Manfred Rieger, Michael Thiele, Geert C. Mudde, Juergen Muellberg, Rene Hoet
-
Publication number: 20100260768Abstract: The present invention relates to monoclonal antibodies and antigen-binding portions thereof that specifically bind to the C-terminal or the center region of macrophage migration inhibitory factor (MIF). These anti-MIF antibodies and antigen-binding portions thereof further inhibit human MIF biological function. The invention also relates to isolated heavy and light chain immunoglobulins derived from anti-MIF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to a method of identifying anti-MIF antibodies, pharmaceutical compositions comprising these antibodies and a method of using these antibodies and compositions for the treatment of MIF-related conditions.Type: ApplicationFiled: April 26, 2010Publication date: October 14, 2010Applicants: Baxter International Inc., Baxter Healthcare S.A., Dyax Corp.Inventors: Randolf Kerschbaumer, Friedrich Scheiflinger, Manfred Rieger, Michael Thiele, Geert C. Mudde, Juergen Muellberg, Rene Hoet
-
Publication number: 20090220521Abstract: The present invention relates to monoclonal antibodies and antigen-binding portions thereof that specifically bind to the C-terminal or the center region of macrophage migration inhibitory factor (MIF). These anti-MIF antibodies and antigen-binding portions thereof further inhibit human MIF biological function. The invention also relates to isolated heavy and light chain immunoglobulins derived from anti-MIF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to a method of identifying anti-MIF antibodies, pharmaceutical compositions comprising these antibodies and a method of using these antibodies and compositions for the treatment of MIF-related conditions.Type: ApplicationFiled: December 30, 2008Publication date: September 3, 2009Inventors: Randolf Kerschbaumer, Friedrich Scheiflinger, Manfred Rieger, Michael Thiele, Geert C. Mudde, Juergen Muellberg, Rene Hoet
-
Patent number: 5128495Abstract: The said compounds are prepared by reaction of trialkyl phosphites with phosphorus trichloride and/or dichlorophosphinous acid monoalkyl esters at -20 to +100.degree. C. and direct subsequent reaction with alkylmagnesium chloride or alkylmagnesium bromide at -60 to +50.degree. C. and subsequent separation of the desired compounds from the distillate of the volatile compounds. Dialkyl alkylphosphonites and monoalkyl dialkylphosphinites are thus obtained without troublesome and expensive purification of intermediates. The phosphorus-containing esters produced are, for their part, useful intermediates, for example for the preparation of flame retardants and plant protection agents.Type: GrantFiled: April 5, 1990Date of Patent: July 7, 1992Assignee: Hoechst AktiengesellschaftInventors: Gunter Scheffel, Michael Thiele